ES2569665T3 - Derivados de imidazol condensados útiles como inhibidores de IDO - Google Patents
Derivados de imidazol condensados útiles como inhibidores de IDO Download PDFInfo
- Publication number
- ES2569665T3 ES2569665T3 ES12715295.7T ES12715295T ES2569665T3 ES 2569665 T3 ES2569665 T3 ES 2569665T3 ES 12715295 T ES12715295 T ES 12715295T ES 2569665 T3 ES2569665 T3 ES 2569665T3
- Authority
- ES
- Spain
- Prior art keywords
- imidazo
- isoindole
- ethanol
- ethyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title description 9
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- -1 3- indolyl Chemical group 0.000 claims abstract description 237
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 26
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 19
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- APZFWCOFDKAMPQ-UHFFFAOYSA-N 1-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC21OCCO2 APZFWCOFDKAMPQ-UHFFFAOYSA-N 0.000 claims description 4
- BMDIVHVHCUXCED-UHFFFAOYSA-N 1-(2-aminophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound NC1=CC=CC=C1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 BMDIVHVHCUXCED-UHFFFAOYSA-N 0.000 claims description 4
- FCJBROSAFICRIB-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound ClC1=CC=CC=C1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 FCJBROSAFICRIB-UHFFFAOYSA-N 0.000 claims description 4
- XKHZICCQURTELE-UHFFFAOYSA-N 1-(3-aminophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound NC1=CC=CC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)=C1 XKHZICCQURTELE-UHFFFAOYSA-N 0.000 claims description 4
- BBYFCKZHLMMOBN-UHFFFAOYSA-N 1-(4,4-difluorocyclohexyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(F)(F)CC1 BBYFCKZHLMMOBN-UHFFFAOYSA-N 0.000 claims description 4
- FPKRCRNJVIHTNG-UHFFFAOYSA-N 1-(4,4-difluorocyclohexyl)-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(F)(F)CC1 FPKRCRNJVIHTNG-UHFFFAOYSA-N 0.000 claims description 4
- JDTLXYAWWCQLKO-UHFFFAOYSA-N 1-(4-aminophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound C1=CC(N)=CC=C1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 JDTLXYAWWCQLKO-UHFFFAOYSA-N 0.000 claims description 4
- PRUMALLZQVUWMP-UHFFFAOYSA-N 1-[4-(cyclopropylmethylidene)cyclohexyl]-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1=CC1CC1 PRUMALLZQVUWMP-UHFFFAOYSA-N 0.000 claims description 4
- BHPMBGLATDMBIK-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2,2-dimethylpropan-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 BHPMBGLATDMBIK-UHFFFAOYSA-N 0.000 claims description 4
- TZLKQKCGJBWURI-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 TZLKQKCGJBWURI-UHFFFAOYSA-N 0.000 claims description 4
- OCMQWRLTHDLIRS-UHFFFAOYSA-N 1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanamine Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(N)C1CCCCC1 OCMQWRLTHDLIRS-UHFFFAOYSA-N 0.000 claims description 4
- AKOIXTSNUPHRQM-UHFFFAOYSA-N 1-cyclohexyl-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCCCC1 AKOIXTSNUPHRQM-UHFFFAOYSA-N 0.000 claims description 4
- IDAMUBBXWPKKDM-UHFFFAOYSA-N 1-cyclohexyl-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound C1=2C(F)=CC=CC=2C2=CN=CN2C1CC(=O)C1CCCCC1 IDAMUBBXWPKKDM-UHFFFAOYSA-N 0.000 claims description 4
- GZLGDNBVPZDDHN-UHFFFAOYSA-N 1-cyclohexyl-2-(8-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=C(F)C=C2C2=CN=CN2C1CC(O)C1CCCCC1 GZLGDNBVPZDDHN-UHFFFAOYSA-N 0.000 claims description 4
- IKPLNLUUWHVZPW-UHFFFAOYSA-N 1-cyclohexyl-2-(9-methoxy-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound N12C=NC=C2C=2C(OC)=CC=CC=2C1CC(O)C1CCCCC1 IKPLNLUUWHVZPW-UHFFFAOYSA-N 0.000 claims description 4
- MTNKITWGIJLVJD-UHFFFAOYSA-N 1-cyclopentyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCCC1 MTNKITWGIJLVJD-UHFFFAOYSA-N 0.000 claims description 4
- XGPDPODYEGNQHX-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1,3-thiazol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CN=CS1 XGPDPODYEGNQHX-UHFFFAOYSA-N 0.000 claims description 4
- RVUYIEVFJNWBDV-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(2-nitrophenyl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC=C1[N+]([O-])=O RVUYIEVFJNWBDV-UHFFFAOYSA-N 0.000 claims description 4
- RLXCXBWRZHJHBP-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(3-nitrophenyl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC([N+]([O-])=O)=C1 RLXCXBWRZHJHBP-UHFFFAOYSA-N 0.000 claims description 4
- MLYALVMQZHXKJU-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(3-nitrophenyl)ethanone Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)CC2N3C=NC=C3C3=CC=CC=C32)=C1 MLYALVMQZHXKJU-UHFFFAOYSA-N 0.000 claims description 4
- VVBPUZHWIHLPDF-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylidenecyclohexyl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(=C)CC1 VVBPUZHWIHLPDF-UHFFFAOYSA-N 0.000 claims description 4
- NVAQHNXPNVUNHA-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-phenylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC=C1 NVAQHNXPNVUNHA-UHFFFAOYSA-N 0.000 claims description 4
- KMIOWWHRINGLFM-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylcyclohexyl)ethanol Chemical compound C1CC(C)CCC1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 KMIOWWHRINGLFM-UHFFFAOYSA-N 0.000 claims description 4
- NDSJYFMKCXEXFW-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(furan-2-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1=CC=CO1 NDSJYFMKCXEXFW-UHFFFAOYSA-N 0.000 claims description 4
- TYYSLXOKEGQSTO-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(iodomethylidene)cyclohexyl]ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(=CI)CC1 TYYSLXOKEGQSTO-UHFFFAOYSA-N 0.000 claims description 4
- YUHFEKHIZVIKIR-UHFFFAOYSA-N 5-(2-cyclohexyl-2-hydroxyethyl)-5h-imidazo[5,1-a]isoindol-9-ol Chemical compound C12=CC=CC(O)=C2C2=CN=CN2C1CC(O)C1CCCCC1 YUHFEKHIZVIKIR-UHFFFAOYSA-N 0.000 claims description 4
- HIFKHTGNHWXMNH-UHFFFAOYSA-N [4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-thiophen-2-ylmethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)C1=CC=CS1 HIFKHTGNHWXMNH-UHFFFAOYSA-N 0.000 claims description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims description 4
- PPEUMDWFICZDCN-SILNSSARSA-N (nz)-n-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethylidene]hydroxylamine Chemical compound C12=CC=CC=C2C2=CN=CN2C1C/C(=N/O)C1CCCCC1 PPEUMDWFICZDCN-SILNSSARSA-N 0.000 claims description 3
- PESZLYAORBUEKU-UHFFFAOYSA-N 1-(2,4-dimethylfuran-3-yl)-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound CC1=COC(C)=C1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 PESZLYAORBUEKU-UHFFFAOYSA-N 0.000 claims description 3
- QRYSBXVPYUPWPS-UHFFFAOYSA-N 1-(2-aminophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound NC1=CC=CC=C1C(O)CC1N2C=NC=C2C2=CC=CC=C21 QRYSBXVPYUPWPS-UHFFFAOYSA-N 0.000 claims description 3
- TTXRSWJNADPSSS-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC=C1Cl TTXRSWJNADPSSS-UHFFFAOYSA-N 0.000 claims description 3
- KYSMLSSHZDKYMC-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC(Cl)=C1 KYSMLSSHZDKYMC-UHFFFAOYSA-N 0.000 claims description 3
- VVIHJLDHSORWDP-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound ClC1=CC=CC(C(=O)CC2N3C=NC=C3C3=CC=CC=C32)=C1 VVIHJLDHSORWDP-UHFFFAOYSA-N 0.000 claims description 3
- CCWQDYPXEQFDAH-UHFFFAOYSA-N 1-(4-aminophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC(N)=CC=C1C(O)CC1N2C=NC=C2C2=CC=CC=C21 CCWQDYPXEQFDAH-UHFFFAOYSA-N 0.000 claims description 3
- JNNMYZDYWKIDMJ-UHFFFAOYSA-N 1-(5h-imidazo[5,1-a]isoindol-5-yl)-2-methylpropan-2-ol Chemical compound C1=CC=C2C3=CN=CN3C(CC(C)(O)C)C2=C1 JNNMYZDYWKIDMJ-UHFFFAOYSA-N 0.000 claims description 3
- UYEVJNPAUYAELH-UHFFFAOYSA-N 1-cyclohex-3-en-1-yl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC=CC1 UYEVJNPAUYAELH-UHFFFAOYSA-N 0.000 claims description 3
- YTRRAUACYORZLX-UHFFFAOYSA-N 1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCCCC1 YTRRAUACYORZLX-UHFFFAOYSA-N 0.000 claims description 3
- LXUFCLWCRAGUAS-UHFFFAOYSA-N 1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)propan-1-ol Chemical compound C12=CC=CC=C2C2=CN=CN2C1C(C)C(O)C1CCCCC1 LXUFCLWCRAGUAS-UHFFFAOYSA-N 0.000 claims description 3
- VXLCRYSJAYJVGS-UHFFFAOYSA-N 1-cyclohexyl-3-(5h-imidazo[5,1-a]isoindol-5-yl)propan-2-ol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)CC1CCCCC1 VXLCRYSJAYJVGS-UHFFFAOYSA-N 0.000 claims description 3
- OBBNZIWTQPASCP-UHFFFAOYSA-N 1-cyclohexyl-3-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)propan-2-ol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)CC1CCCCC1 OBBNZIWTQPASCP-UHFFFAOYSA-N 0.000 claims description 3
- VBGYBTPGGDXLMD-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1,3-thiazol-4-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CSC=N1 VBGYBTPGGDXLMD-UHFFFAOYSA-N 0.000 claims description 3
- DIXRFDWKFCYQSI-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(2-nitrophenyl)ethanone Chemical compound [O-][N+](=O)C1=CC=CC=C1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 DIXRFDWKFCYQSI-UHFFFAOYSA-N 0.000 claims description 3
- JXTJKNFGBORUEK-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(oxan-4-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCOCC1 JXTJKNFGBORUEK-UHFFFAOYSA-N 0.000 claims description 3
- FEUNICQQIZEYDV-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)acetonitrile Chemical compound C1=CC=C2C3=CN=CN3C(CC#N)C2=C1 FEUNICQQIZEYDV-UHFFFAOYSA-N 0.000 claims description 3
- SHRFEOBHMXWKSI-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(3-methylimidazol-4-yl)ethanol Chemical compound CN1C=NC=C1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 SHRFEOBHMXWKSI-UHFFFAOYSA-N 0.000 claims description 3
- YGACXVRLDHEXKY-UHFFFAOYSA-N 4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexan-1-ol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(O)CC1 YGACXVRLDHEXKY-UHFFFAOYSA-N 0.000 claims description 3
- OYGJBQURZPTNSK-UHFFFAOYSA-N 4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexan-1-one Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(=O)CC1 OYGJBQURZPTNSK-UHFFFAOYSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- YTRRAUACYORZLX-DAFXYXGESA-N (1s)-1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1([C@H](CC2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-DAFXYXGESA-N 0.000 claims description 2
- ISCDNERVCHFOSZ-UHFFFAOYSA-N 1-[1-(2-aminopyrimidin-4-yl)piperidin-4-yl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound NC1=NC=CC(N2CCC(CC2)C(O)CC2N3C=NC=C3C3=CC=CC=C32)=N1 ISCDNERVCHFOSZ-UHFFFAOYSA-N 0.000 claims description 2
- NWDKPBHGOWJAIE-UHFFFAOYSA-N 1-[4-(difluoromethylidene)cyclohexyl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(=C(F)F)CC1 NWDKPBHGOWJAIE-UHFFFAOYSA-N 0.000 claims description 2
- JTROHOGCUWMDID-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-(2-methyl-1,3-thiazol-5-yl)ethanone Chemical compound S1C(C)=NC=C1CC(=O)N1CCC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)CC1 JTROHOGCUWMDID-UHFFFAOYSA-N 0.000 claims description 2
- GRTMSCAOJVEIAZ-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-(3-hydroxyphenyl)ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CC=CC(O)=C1 GRTMSCAOJVEIAZ-UHFFFAOYSA-N 0.000 claims description 2
- MQBRBOPIMMPJSH-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-3,3-dimethylbutan-1-one Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 MQBRBOPIMMPJSH-UHFFFAOYSA-N 0.000 claims description 2
- NGSMNKAYPOQDKS-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[1-(2-phenylethanimidoyl)piperidin-4-yl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=N)CC1=CC=CC=C1 NGSMNKAYPOQDKS-UHFFFAOYSA-N 0.000 claims description 2
- FLGBJLSDZNXFTD-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(1,3-oxazol-2-ylmethoxy)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC1OCC1=NC=CO1 FLGBJLSDZNXFTD-UHFFFAOYSA-N 0.000 claims description 2
- PDXQXGJDMVXEOS-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(2,2,2-trifluoroethylidene)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(=CC(F)(F)F)CC1 PDXQXGJDMVXEOS-UHFFFAOYSA-N 0.000 claims description 2
- IDIMZVATARIKGW-UHFFFAOYSA-N 2-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexylidene]acetonitrile Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(=CC#N)CC1 IDIMZVATARIKGW-UHFFFAOYSA-N 0.000 claims description 2
- GOTWJZVRVPDDMN-UHFFFAOYSA-N 2-cyclopropyl-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1CC1 GOTWJZVRVPDDMN-UHFFFAOYSA-N 0.000 claims description 2
- RDRKTEAOMSPEIT-UHFFFAOYSA-N 3,3-difluoro-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CC(F)(F)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 RDRKTEAOMSPEIT-UHFFFAOYSA-N 0.000 claims description 2
- KHRSALHCWRYRRN-UHFFFAOYSA-N 4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]-n'-phenylpiperidine-1-carboximidamide Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=N)NC1=CC=CC=C1 KHRSALHCWRYRRN-UHFFFAOYSA-N 0.000 claims description 2
- NSQXEQFBHZFTES-UHFFFAOYSA-N 4-[2-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-oxoethyl]benzoic acid Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CC=C(C(O)=O)C=C1 NSQXEQFBHZFTES-UHFFFAOYSA-N 0.000 claims description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 2
- PNYPJSJTDDEXRR-UHFFFAOYSA-N 5h-imidazo[5,1-a]isoindole Chemical compound C1=CC=C2C3=CN=CN3CC2=C1 PNYPJSJTDDEXRR-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- ZBLUTUCNUZUDLC-UHFFFAOYSA-N 1-[1-(4-aminopyrimidin-2-yl)piperidin-4-yl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound NC1=CC=NC(N2CCC(CC2)C(O)CC2N3C=NC=C3C3=CC=CC=C32)=N1 ZBLUTUCNUZUDLC-UHFFFAOYSA-N 0.000 claims 1
- OZXLCOHVTZVPNC-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(oxan-4-ylmethoxy)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC1OCC1CCOCC1 OZXLCOHVTZVPNC-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 18
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract description 18
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 18
- 239000001257 hydrogen Substances 0.000 abstract description 18
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 abstract description 17
- 125000000217 alkyl group Chemical group 0.000 abstract description 16
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract description 15
- 229910052736 halogen Inorganic materials 0.000 abstract description 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract description 11
- 125000003118 aryl group Chemical group 0.000 abstract description 11
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 8
- 150000002367 halogens Chemical group 0.000 abstract description 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 2
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 121
- 239000000203 mixture Substances 0.000 description 90
- 238000005481 NMR spectroscopy Methods 0.000 description 80
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 23
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 23
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000012043 crude product Substances 0.000 description 17
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 16
- 239000007832 Na2SO4 Substances 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 235000011152 sodium sulphate Nutrition 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000012267 brine Substances 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- HLYRMJZSHCAAAA-UHFFFAOYSA-N 6-fluoro-5H-imidazo[5,1-a]isoindole Chemical compound FC1=C2CN3C(C2=CC=C1)=CN=C3 HLYRMJZSHCAAAA-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- FRFMOJJXJLFIDQ-UHFFFAOYSA-N (3-fluoro-2-hydroxyphenyl)-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]methanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)C1=CC=CC(F)=C1O FRFMOJJXJLFIDQ-UHFFFAOYSA-N 0.000 description 3
- SBGDHJQZWJCENG-UHFFFAOYSA-N (4-fluorophenyl)-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]methanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)C1=CC=C(F)C=C1 SBGDHJQZWJCENG-UHFFFAOYSA-N 0.000 description 3
- QJJZDVYBJWAXFJ-UHFFFAOYSA-N 1-(1-benzylsulfonylpiperidin-4-yl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1S(=O)(=O)CC1=CC=CC=C1 QJJZDVYBJWAXFJ-UHFFFAOYSA-N 0.000 description 3
- ORGKDAJDXPSGMH-UHFFFAOYSA-N 1-[4-(2-hydroxyethylidene)cyclohexyl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1CC(=CCO)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 ORGKDAJDXPSGMH-UHFFFAOYSA-N 0.000 description 3
- DUECNPBMYIFWGD-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-pyrimidin-5-ylethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CN=CN=C1 DUECNPBMYIFWGD-UHFFFAOYSA-N 0.000 description 3
- JYHYESPWJNAVOK-UHFFFAOYSA-N 1-cyclohexyl-2-imidazo[1,5-b]isoindol-5-ylideneethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1=CC(O)C1CCCCC1 JYHYESPWJNAVOK-UHFFFAOYSA-N 0.000 description 3
- WRGKBSDYTGFYGX-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CC=C(F)C(F)=C1 WRGKBSDYTGFYGX-UHFFFAOYSA-N 0.000 description 3
- GCUYSCRDNLRJNF-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CC=C(F)C=C1 GCUYSCRDNLRJNF-UHFFFAOYSA-N 0.000 description 3
- CMQVUMXNOXRMHF-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1-methylimidazol-4-yl)ethanol Chemical compound CN1C=NC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)=C1 CMQVUMXNOXRMHF-UHFFFAOYSA-N 0.000 description 3
- DXHZTNYHUDMHMF-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(trifluoromethyl)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(C(F)(F)F)CC1 DXHZTNYHUDMHMF-UHFFFAOYSA-N 0.000 description 3
- XRBKUEHFWMLWQX-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-piperidin-4-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCNCC1 XRBKUEHFWMLWQX-UHFFFAOYSA-N 0.000 description 3
- FNGDHPYZIOFVLB-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-pyridin-2-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC=N1 FNGDHPYZIOFVLB-UHFFFAOYSA-N 0.000 description 3
- JNVJGLYGJXLWMV-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-pyridin-3-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CN=C1 JNVJGLYGJXLWMV-UHFFFAOYSA-N 0.000 description 3
- RLYSBDKKQFJXQY-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-pyridin-4-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=NC=C1 RLYSBDKKQFJXQY-UHFFFAOYSA-N 0.000 description 3
- SMPOUDVZNQHGAJ-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-spiro[2.5]octan-6-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC21CC2 SMPOUDVZNQHGAJ-UHFFFAOYSA-N 0.000 description 3
- ZYPRRGPKYOLLOE-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)acetic acid Chemical compound C1=CC=C2C3=CN=CN3C(CC(=O)O)C2=C1 ZYPRRGPKYOLLOE-UHFFFAOYSA-N 0.000 description 3
- DRQXMMIFVYDSFP-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(1-methylimidazol-2-yl)ethanol Chemical compound CN1C=CN=C1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 DRQXMMIFVYDSFP-UHFFFAOYSA-N 0.000 description 3
- PMNBNUNUHZZMCV-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-propan-2-ylidenecyclohexyl)ethanol Chemical compound C1CC(=C(C)C)CCC1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 PMNBNUNUHZZMCV-UHFFFAOYSA-N 0.000 description 3
- YQEVXFURUXEILY-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(trifluoromethyl)cyclohexyl]ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(C(F)(F)F)CC1 YQEVXFURUXEILY-UHFFFAOYSA-N 0.000 description 3
- CLBMXXZZZNDZBL-UHFFFAOYSA-N 2-(9-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylcyclohexyl)ethanol Chemical compound C1CC(C)CCC1C(O)CC1N2C=NC=C2C2=C(F)C=CC=C21 CLBMXXZZZNDZBL-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100022297 Integrin alpha-X Human genes 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 3
- FDUHADIZUWTWAZ-UHFFFAOYSA-N cyclohexyl-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]methanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)C1CCCCC1 FDUHADIZUWTWAZ-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- YTRRAUACYORZLX-SJLPKXTDSA-N (1r)-1-cyclohexyl-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C1([C@@H](C[C@H]2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-SJLPKXTDSA-N 0.000 description 2
- YTRRAUACYORZLX-FUHWJXTLSA-N (1r)-1-cyclohexyl-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C1([C@@H](C[C@@H]2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-FUHWJXTLSA-N 0.000 description 2
- YTRRAUACYORZLX-AEFFLSMTSA-N (1s)-1-cyclohexyl-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C1([C@H](C[C@H]2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-AEFFLSMTSA-N 0.000 description 2
- YTRRAUACYORZLX-WMZOPIPTSA-N (1s)-1-cyclohexyl-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C1([C@H](C[C@@H]2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-WMZOPIPTSA-N 0.000 description 2
- KVZKINKUBBROSQ-ICXLUZGWSA-N (2s)-2-amino-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-3-phenylpropan-1-one Chemical compound C([C@H](N)C(=O)N1CCC(CC1)C(O)CC1N2C=NC=C2C2=CC=CC=C21)C1=CC=CC=C1 KVZKINKUBBROSQ-ICXLUZGWSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- GZGPRZYZKBQPBQ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decane Chemical compound O1CCOC11CCCCC1 GZGPRZYZKBQPBQ-UHFFFAOYSA-N 0.000 description 2
- QLKHQKNGJQFYIG-UHFFFAOYSA-N 1-(azetidin-3-yl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CNC1 QLKHQKNGJQFYIG-UHFFFAOYSA-N 0.000 description 2
- MRJBMWLOCDYCAN-UHFFFAOYSA-N 1-(cyclohexen-1-yl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CCCCC1 MRJBMWLOCDYCAN-UHFFFAOYSA-N 0.000 description 2
- ADXRHXZIAQWYPA-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-pyridin-4-ylethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CC=NC=C1 ADXRHXZIAQWYPA-UHFFFAOYSA-N 0.000 description 2
- TXXNCTKTORUINM-UHFFFAOYSA-N 1-cyclohex-3-en-1-yl-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC=CC1 TXXNCTKTORUINM-UHFFFAOYSA-N 0.000 description 2
- ARCOTNOWDCVWJS-UHFFFAOYSA-N 2-(1-tritylimidazol-4-yl)benzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 ARCOTNOWDCVWJS-UHFFFAOYSA-N 0.000 description 2
- LEJRMYUCBJPDLO-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(2-phenylmethoxyethylidene)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC1=CCOCC1=CC=CC=C1 LEJRMYUCBJPDLO-UHFFFAOYSA-N 0.000 description 2
- UYCYZTOKAZCNHV-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-n-methylacetamide Chemical compound C1=CC=C2C3=CN=CN3C(CC(=O)NC)C2=C1 UYCYZTOKAZCNHV-UHFFFAOYSA-N 0.000 description 2
- PLLNFKSVVIRLCV-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)acetaldehyde Chemical class C1=CC=C2C3=CN=CN3C(CC=O)C2=C1 PLLNFKSVVIRLCV-UHFFFAOYSA-N 0.000 description 2
- KBIQFEDIQLEELY-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylidenecyclohexyl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(=C)CC1 KBIQFEDIQLEELY-UHFFFAOYSA-N 0.000 description 2
- JHZQZKVZAABZIH-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-propan-2-ylidenecyclohexyl)ethanone Chemical compound C1CC(=C(C)C)CCC1C(=O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 JHZQZKVZAABZIH-UHFFFAOYSA-N 0.000 description 2
- KECJSORXVGLSAH-UHFFFAOYSA-N 4-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethoxy]-4-oxobutanoic acid Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(OC(=O)CCC(=O)O)C1CCCCC1 KECJSORXVGLSAH-UHFFFAOYSA-N 0.000 description 2
- JIVGYYJPJKYZPP-UHFFFAOYSA-N 4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexan-1-ol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(O)CC1 JIVGYYJPJKYZPP-UHFFFAOYSA-N 0.000 description 2
- DFYHDIYAMRTKAI-ZHACJKMWSA-N 5-[(e)-2-cyclohexylethenyl]-5h-imidazo[5,1-a]isoindole Chemical compound C1CCCCC1\C=C\C1N2C=NC=C2C2=CC=CC=C21 DFYHDIYAMRTKAI-ZHACJKMWSA-N 0.000 description 2
- UKFHFLJKSPYLED-YMISUZCDSA-N 5-o-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl] 1-o-methyl (2s)-2-aminopentanedioate Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(OC(=O)CC[C@H](N)C(=O)OC)C1CCCCC1 UKFHFLJKSPYLED-YMISUZCDSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- XKYDXVDTWDQCAV-JSOIOWGOSA-N [4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-[(2s)-pyrrolidin-2-yl]methanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)[C@@H]1CCCN1 XKYDXVDTWDQCAV-JSOIOWGOSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- XAVNWNCTXQDFLF-UHFFFAOYSA-N methyl piperidin-1-ium-4-carboxylate;chloride Chemical compound Cl.COC(=O)C1CCNCC1 XAVNWNCTXQDFLF-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- YTRRAUACYORZLX-UHUGOGIASA-N (1r)-1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1([C@@H](CC2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-UHUGOGIASA-N 0.000 description 1
- DGUWACLYDSWXRZ-UHFFFAOYSA-N (2-formylphenyl)boronic acid Chemical class OB(O)C1=CC=CC=C1C=O DGUWACLYDSWXRZ-UHFFFAOYSA-N 0.000 description 1
- RRQRZNAPWJNCHH-MBIQTGHCSA-N (5s)-5-(2-cyclohexyl-2-hydroxyethyl)-5h-imidazo[5,1-a]isoindol-6-ol Chemical compound C([C@@H]1N2C=NC=C2C2=C1C(=CC=C2)O)C(O)C1CCCCC1 RRQRZNAPWJNCHH-MBIQTGHCSA-N 0.000 description 1
- AAKIRSZQUYRJLZ-MDZDMXLPSA-N (e)-3-(2-chloro-6-iodophenyl)-1-cyclohexylprop-2-en-1-one Chemical compound ClC1=CC=CC(I)=C1\C=C\C(=O)C1CCCCC1 AAKIRSZQUYRJLZ-MDZDMXLPSA-N 0.000 description 1
- JBYQKBXQMYFXQN-CMDGGOBGSA-N (e)-3-(2-iodophenyl)-1-(3-nitrophenyl)prop-2-en-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)\C=C\C=2C(=CC=CC=2)I)=C1 JBYQKBXQMYFXQN-CMDGGOBGSA-N 0.000 description 1
- TWHWUGPVOHKDCT-UHFFFAOYSA-N 1-(1-acetylpiperidin-4-yl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound C1CN(C(=O)C)CCC1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 TWHWUGPVOHKDCT-UHFFFAOYSA-N 0.000 description 1
- BMICWQXECZNFSX-UHFFFAOYSA-N 1-(2,5-dimethylfuran-3-yl)-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound O1C(C)=CC(C(O)CC2N3C=NC=C3C3=C2C(=CC=C3)F)=C1C BMICWQXECZNFSX-UHFFFAOYSA-N 0.000 description 1
- FGOYOLFDMZDJPY-UHFFFAOYSA-N 1-(2,5-dimethylfuran-3-yl)-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound O1C(C)=CC(C(=O)CC2N3C=NC=C3C3=C2C(=CC=C3)F)=C1C FGOYOLFDMZDJPY-UHFFFAOYSA-N 0.000 description 1
- WHXGLOURXNAWRM-UHFFFAOYSA-N 1-(2-aminocyclohexyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound NC1CCCCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 WHXGLOURXNAWRM-UHFFFAOYSA-N 0.000 description 1
- AEXLPMGBOMVETQ-UHFFFAOYSA-N 1-(3-aminocyclohexyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1C(N)CCCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 AEXLPMGBOMVETQ-UHFFFAOYSA-N 0.000 description 1
- IEOXCGJGKZJTPW-UHFFFAOYSA-N 1-(4,4-difluorocyclohexyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound C1CC(F)(F)CCC1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 IEOXCGJGKZJTPW-UHFFFAOYSA-N 0.000 description 1
- IVODNVRZNQSBPD-UHFFFAOYSA-N 1-(4,4-difluorocyclohexyl)-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound C1=2C(F)=CC=CC=2C2=CN=CN2C1CC(=O)C1CCC(F)(F)CC1 IVODNVRZNQSBPD-UHFFFAOYSA-N 0.000 description 1
- OWKPEYRNGTVBEN-UHFFFAOYSA-N 1-(4-aminocyclohexyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1CC(N)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 OWKPEYRNGTVBEN-UHFFFAOYSA-N 0.000 description 1
- SXBYEDHYJLPXEQ-UHFFFAOYSA-N 1-(5h-imidazo[5,1-a]isoindol-5-yl)-3-methylbutan-2-ol Chemical compound C1=CC=C2C3=CN=CN3C(CC(O)C(C)C)C2=C1 SXBYEDHYJLPXEQ-UHFFFAOYSA-N 0.000 description 1
- HITQAEDGMLJQHH-UHFFFAOYSA-N 1-[4-(2-hydroxyethylidene)cyclohexyl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound C1CC(=CCO)CCC1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 HITQAEDGMLJQHH-UHFFFAOYSA-N 0.000 description 1
- ATEZPMBIQPSAPX-UHFFFAOYSA-N 1-[4-(aminomethyl)cyclohexyl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1CC(CN)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 ATEZPMBIQPSAPX-UHFFFAOYSA-N 0.000 description 1
- CFSKVFWSULUVNP-LADGPHEKSA-N 1-[4-[(1r)-1-hydroxy-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]piperidin-1-yl]-2-[4-(trifluoromethyl)phenyl]ethanone Chemical compound C1CC([C@@H](C[C@@H]2N3C=NC=C3C3=CC=CC=C32)O)CCN1C(=O)CC1=CC=C(C(F)(F)F)C=C1 CFSKVFWSULUVNP-LADGPHEKSA-N 0.000 description 1
- QICFCOROQQCJFR-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-(4-methylphenyl)ethanone Chemical compound C1=CC(C)=CC=C1CC(=O)N1CCC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)CC1 QICFCOROQQCJFR-UHFFFAOYSA-N 0.000 description 1
- RHYNNJXEEIIUOZ-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-(4-methylsulfonylphenyl)ethanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CC(=O)N1CCC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)CC1 RHYNNJXEEIIUOZ-UHFFFAOYSA-N 0.000 description 1
- WSVIZMUAESJROV-UHFFFAOYSA-N 1-[4-[2-(5h-imidazo[5,1-a]isoindol-5-yl)acetyl]piperidin-1-yl]-2,2-dimethylpropan-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 WSVIZMUAESJROV-UHFFFAOYSA-N 0.000 description 1
- KNCOURWLVNPTET-UHFFFAOYSA-N 1-[4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexyl]-3-phenylurea Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1NC(=O)NC1=CC=CC=C1 KNCOURWLVNPTET-UHFFFAOYSA-N 0.000 description 1
- BGNHGJCIGNAXCA-UHFFFAOYSA-N 1-cyclohexyl-2-(8-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound N12C=NC=C2C2=CC(F)=CC=C2C1CC(=O)C1CCCCC1 BGNHGJCIGNAXCA-UHFFFAOYSA-N 0.000 description 1
- OSGALIUMFAKSAR-UHFFFAOYSA-N 1-cyclohexyl-2-(9-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC(F)=C2C2=CN=CN2C1CC(O)C1CCCCC1 OSGALIUMFAKSAR-UHFFFAOYSA-N 0.000 description 1
- UXZLTVIPWPJEKL-UHFFFAOYSA-N 1-cyclohexyl-2-(9-methoxy-5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound N12C=NC=C2C=2C(OC)=CC=CC=2C1CC(=O)C1CCCCC1 UXZLTVIPWPJEKL-UHFFFAOYSA-N 0.000 description 1
- YTRRAUACYORZLX-PYUWXLGESA-N 1-cyclohexyl-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C([C@H]1N2C=NC=C2C2=CC=CC=C21)C(O)C1CCCCC1 YTRRAUACYORZLX-PYUWXLGESA-N 0.000 description 1
- YTRRAUACYORZLX-ATNAJCNCSA-N 1-cyclohexyl-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C([C@@H]1N2C=NC=C2C2=CC=CC=C21)C(O)C1CCCCC1 YTRRAUACYORZLX-ATNAJCNCSA-N 0.000 description 1
- QYPGWMMBPPVTDC-UHFFFAOYSA-N 1-cyclohexyl-3-(5h-imidazo[5,1-a]isoindol-5-yl)propan-1-ol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CCC(O)C1CCCCC1 QYPGWMMBPPVTDC-UHFFFAOYSA-N 0.000 description 1
- IMYDGBBLZUEUEP-UHFFFAOYSA-N 1-cyclohexyl-3-(5h-imidazo[5,1-a]isoindol-5-yl)propan-2-one Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(=O)CC1CCCCC1 IMYDGBBLZUEUEP-UHFFFAOYSA-N 0.000 description 1
- QTWNFGIVCIXQTB-UHFFFAOYSA-N 1-cyclohexyl-3-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)propan-2-one Chemical compound C1=2C(F)=CC=CC=2C2=CN=CN2C1CC(=O)CC1CCCCC1 QTWNFGIVCIXQTB-UHFFFAOYSA-N 0.000 description 1
- OILPPNKWYFAORW-UHFFFAOYSA-N 1-cyclohexyl-3-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1CCCCC1 OILPPNKWYFAORW-UHFFFAOYSA-N 0.000 description 1
- UZNOAHPKTDYUHV-UHFFFAOYSA-N 1-cyclopentyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(=O)C1CCCC1 UZNOAHPKTDYUHV-UHFFFAOYSA-N 0.000 description 1
- KTVJHFYRWMYEAK-UHFFFAOYSA-N 2-(5H-imidazo[5,1-a]isoindol-5-yl)-1-(1-phenylazetidin-3-yl)ethanol Chemical compound OC(CC1N2C(C3=CC=CC=C13)=CN=C2)C2CN(C2)C2=CC=CC=C2 KTVJHFYRWMYEAK-UHFFFAOYSA-N 0.000 description 1
- POWUHFUPDVSMLU-UHFFFAOYSA-N 2-(5H-imidazo[5,1-a]isoindol-5-yl)-1-(1-pyridin-4-ylpiperidin-4-yl)ethanol Chemical compound C=1N=CN2C=1C1=CC=CC=C1C2CC(O)C1CCN(CC1)C1=CC=NC=C1 POWUHFUPDVSMLU-UHFFFAOYSA-N 0.000 description 1
- DHWPOZDHLCVJMP-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1,3-thiazol-5-yl)ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(=O)C1=CN=CS1 DHWPOZDHLCVJMP-UHFFFAOYSA-N 0.000 description 1
- ANGSZQHCEVNMBD-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1-methylimidazol-4-yl)ethanone Chemical compound CN1C=NC(C(=O)CC2N3C=NC=C3C3=CC=CC=C32)=C1 ANGSZQHCEVNMBD-UHFFFAOYSA-N 0.000 description 1
- DLWAENXUQXYBMY-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1h-imidazol-2-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=NC=CN1 DLWAENXUQXYBMY-UHFFFAOYSA-N 0.000 description 1
- INGRTMFZXCULBB-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1h-imidazol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CNC=N1 INGRTMFZXCULBB-UHFFFAOYSA-N 0.000 description 1
- ROMKWKDMNSXBQV-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylidenecyclohexyl)ethanone Chemical compound C1CC(=C)CCC1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 ROMKWKDMNSXBQV-UHFFFAOYSA-N 0.000 description 1
- VDMDYMCCBSTMCR-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(oxan-4-yl)ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(=O)C1CCOCC1 VDMDYMCCBSTMCR-UHFFFAOYSA-N 0.000 description 1
- ADRVKSRBCDUTBG-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[1-(thiophene-2-carbonyl)piperidin-4-yl]ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(=O)C(CC1)CCN1C(=O)C1=CC=CS1 ADRVKSRBCDUTBG-UHFFFAOYSA-N 0.000 description 1
- HHNUPFRQCKGATB-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(1,3-thiazol-2-ylmethoxy)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC1OCC1=NC=CS1 HHNUPFRQCKGATB-UHFFFAOYSA-N 0.000 description 1
- MXBQCRIBXNWPCM-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(trifluoromethyl)cyclohexyl]ethanone Chemical compound C1CC(C(F)(F)F)CCC1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 MXBQCRIBXNWPCM-UHFFFAOYSA-N 0.000 description 1
- QSCNULJNJWIRQZ-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-piperidin-3-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCCNC1 QSCNULJNJWIRQZ-UHFFFAOYSA-N 0.000 description 1
- FFDKIYUSXKPPQX-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-piperidin-4-ylethanol;dihydrochloride Chemical compound Cl.Cl.C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCNCC1 FFDKIYUSXKPPQX-UHFFFAOYSA-N 0.000 description 1
- NOBMXNSYRBVYJQ-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-pyridin-2-ylethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(=O)C1=CC=CC=N1 NOBMXNSYRBVYJQ-UHFFFAOYSA-N 0.000 description 1
- SUOZHNDVTRWOEB-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-pyridin-3-ylethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(=O)C1=CC=CN=C1 SUOZHNDVTRWOEB-UHFFFAOYSA-N 0.000 description 1
- QMNRTNTUIQJRQZ-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-pyridin-4-ylethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(=O)C1=CC=NC=C1 QMNRTNTUIQJRQZ-UHFFFAOYSA-N 0.000 description 1
- ZBGZCIPWSCHZLD-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-spiro[2.5]octan-6-ylethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(=O)C(CC1)CCC21CC2 ZBGZCIPWSCHZLD-UHFFFAOYSA-N 0.000 description 1
- VQGLVXRSMONFQT-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC=C2C3=CN=CN3C(CCO)C2=C1 VQGLVXRSMONFQT-UHFFFAOYSA-N 0.000 description 1
- INSWVLVOFHQFIC-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(1,3-thiazol-2-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1=NC=CS1 INSWVLVOFHQFIC-UHFFFAOYSA-N 0.000 description 1
- CHTSIMRFIJVBCC-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(1-methylpiperidin-4-yl)ethanol Chemical compound C1CN(C)CCC1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 CHTSIMRFIJVBCC-UHFFFAOYSA-N 0.000 description 1
- BCHGWSORPZYBIV-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(3-methylimidazol-4-yl)ethanone Chemical compound CN1C=NC=C1C(=O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 BCHGWSORPZYBIV-UHFFFAOYSA-N 0.000 description 1
- LKAMFCZCADZRAE-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylcyclohexyl)ethanone Chemical compound C1CC(C)CCC1C(=O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 LKAMFCZCADZRAE-UHFFFAOYSA-N 0.000 description 1
- BZCCNFXYAJDUTN-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylidenecyclohexyl)ethanone Chemical compound C1=2C(F)=CC=CC=2C2=CN=CN2C1CC(=O)C1CCC(=C)CC1 BZCCNFXYAJDUTN-UHFFFAOYSA-N 0.000 description 1
- CVGWUJPLKZRSOP-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(furan-2-yl)ethanone Chemical compound C1=2C(F)=CC=CC=2C2=CN=CN2C1CC(=O)C1=CC=CO1 CVGWUJPLKZRSOP-UHFFFAOYSA-N 0.000 description 1
- LYEKLDIEZJELAF-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(iodomethylidene)cyclohexyl]ethanone Chemical compound C1=2C(F)=CC=CC=2C2=CN=CN2C1CC(=O)C1CCC(=CI)CC1 LYEKLDIEZJELAF-UHFFFAOYSA-N 0.000 description 1
- ZGHKSCMLBRFMSY-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(trifluoromethyl)cyclohexyl]ethanone Chemical compound C1=2C(F)=CC=CC=2C2=CN=CN2C1CC(=O)C1CCC(C(F)(F)F)CC1 ZGHKSCMLBRFMSY-UHFFFAOYSA-N 0.000 description 1
- BBGLGXYHCAZLIV-UHFFFAOYSA-N 2-(9-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylcyclohexyl)ethanone Chemical compound C1CC(C)CCC1C(=O)CC1N2C=NC=C2C2=C(F)C=CC=C21 BBGLGXYHCAZLIV-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- YXPVIJYOABHAIM-UHFFFAOYSA-N 2-cyclopentyl-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1CCCC1 YXPVIJYOABHAIM-UHFFFAOYSA-N 0.000 description 1
- HWGCYDKBCWMBGP-UHFFFAOYSA-N 2-dimethoxyphosphoryl-1-(1-methylimidazol-2-yl)ethanone Chemical compound COP(=O)(OC)CC(=O)C1=NC=CN1C HWGCYDKBCWMBGP-UHFFFAOYSA-N 0.000 description 1
- PHMWHLHIBPTMJK-UHFFFAOYSA-N 2-dimethoxyphosphoryl-1-(1-methylimidazol-4-yl)ethanone Chemical compound COP(=O)(OC)CC(=O)C1=CN(C)C=N1 PHMWHLHIBPTMJK-UHFFFAOYSA-N 0.000 description 1
- USAIAEHYUWJEQF-UHFFFAOYSA-N 2-dimethoxyphosphoryl-1-(furan-2-yl)ethanone Chemical compound COP(=O)(OC)CC(=O)C1=CC=CO1 USAIAEHYUWJEQF-UHFFFAOYSA-N 0.000 description 1
- MYHDGAADXBYIBQ-UHFFFAOYSA-N 2-dimethoxyphosphoryl-1-pyridin-3-ylethanone Chemical compound COP(=O)(OC)CC(=O)C1=CC=CN=C1 MYHDGAADXBYIBQ-UHFFFAOYSA-N 0.000 description 1
- SRVOKSJOOBNPGR-UHFFFAOYSA-N 2-fluoro-6-(1-tritylimidazol-4-yl)benzaldehyde Chemical compound FC1=CC=CC(C=2N=CN(C=2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C=O SRVOKSJOOBNPGR-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- RFIHPDORVWRDHP-UHFFFAOYSA-N 3-methoxy-2-(1-tritylimidazol-4-yl)benzaldehyde Chemical compound COC1=CC=CC(C=O)=C1C1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 RFIHPDORVWRDHP-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- AVUZOXPRZPEVIP-UHFFFAOYSA-N 4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexane-1-carboxylic acid Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(C(O)=O)CC1 AVUZOXPRZPEVIP-UHFFFAOYSA-N 0.000 description 1
- HNXIYVNNEMRRDH-UHFFFAOYSA-N 4-chloro-2-(1-tritylimidazol-4-yl)benzaldehyde Chemical compound ClC1=CC=C(C=O)C(C=2N=CN(C=2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 HNXIYVNNEMRRDH-UHFFFAOYSA-N 0.000 description 1
- XUOWHWXHQGDCFG-UHFFFAOYSA-N 4-fluoro-2-(1-tritylimidazol-4-yl)benzaldehyde Chemical compound FC1=CC=C(C=O)C(C=2N=CN(C=2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 XUOWHWXHQGDCFG-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- HPNZYMVCUOAISF-UHFFFAOYSA-N 5-chloro-2-(1-tritylimidazol-4-yl)benzaldehyde Chemical compound O=CC1=CC(Cl)=CC=C1C1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 HPNZYMVCUOAISF-UHFFFAOYSA-N 0.000 description 1
- MNQVIQUENHTTMH-BQPARCGPSA-N 5-o-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl] 1-o-methyl (2s)-2-aminopentanedioate;dihydrochloride Chemical compound Cl.Cl.C12=CC=CC=C2C2=CN=CN2C1CC(OC(=O)CC[C@H](N)C(=O)OC)C1CCCCC1 MNQVIQUENHTTMH-BQPARCGPSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- YGACXVRLDHEXKY-DMMRXEJWSA-N C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)[C@H]1CC[C@H](O)CC1 Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-DMMRXEJWSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- NZFJSPZESXZKRZ-NRCGHCQOSA-N N([C@H]1CC[C@@H](CC1)C(CC1N2C=NC=C2C2=CC=CC=C21)=O)C(=O)C1=CC=CC=C1 Chemical compound N([C@H]1CC[C@@H](CC1)C(CC1N2C=NC=C2C2=CC=CC=C21)=O)C(=O)C1=CC=CC=C1 NZFJSPZESXZKRZ-NRCGHCQOSA-N 0.000 description 1
- GGPLEOHHSWNDKN-HHVDKCBWSA-N N([C@H]1CC[C@@H](CC1)C(CC1N2C=NC=C2C2=CC=CC=C21)O)C(=O)C1=CC=CC=C1 Chemical compound N([C@H]1CC[C@@H](CC1)C(CC1N2C=NC=C2C2=CC=CC=C21)O)C(=O)C1=CC=CC=C1 GGPLEOHHSWNDKN-HHVDKCBWSA-N 0.000 description 1
- NZFJSPZESXZKRZ-RYKNDIGVSA-N N([C@H]1CC[C@H](CC1)C(CC1N2C=NC=C2C2=CC=CC=C21)=O)C(=O)C1=CC=CC=C1 Chemical compound N([C@H]1CC[C@H](CC1)C(CC1N2C=NC=C2C2=CC=CC=C21)=O)C(=O)C1=CC=CC=C1 NZFJSPZESXZKRZ-RYKNDIGVSA-N 0.000 description 1
- GGPLEOHHSWNDKN-DVVBKOKQSA-N N([C@H]1CC[C@H](CC1)C(CC1N2C=NC=C2C2=CC=CC=C21)O)C(=O)C1=CC=CC=C1 Chemical compound N([C@H]1CC[C@H](CC1)C(CC1N2C=NC=C2C2=CC=CC=C21)O)C(=O)C1=CC=CC=C1 GGPLEOHHSWNDKN-DVVBKOKQSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- QOAPZXZTWGXZBH-PBVHZTIHSA-N O([C@H]1CC[C@@H](CC1)C(CC1N2C=NC=C2C2=CC=CC=C21)=O)CC1=CC=CC=C1 Chemical compound O([C@H]1CC[C@@H](CC1)C(CC1N2C=NC=C2C2=CC=CC=C21)=O)CC1=CC=CC=C1 QOAPZXZTWGXZBH-PBVHZTIHSA-N 0.000 description 1
- SCWXAHFBXGCWHC-OMOPZRMTSA-N O([C@H]1CC[C@@H](CC1)[C@@H](CC1N2C=NC=C2C2=C1C(=CC=C2)F)O)CC1=CC=CC=C1 Chemical compound O([C@H]1CC[C@@H](CC1)[C@@H](CC1N2C=NC=C2C2=C1C(=CC=C2)F)O)CC1=CC=CC=C1 SCWXAHFBXGCWHC-OMOPZRMTSA-N 0.000 description 1
- BGZYLMZZDLEDEY-IBXKDZKYSA-N O([C@H]1CC[C@@H](CC1)[C@@H](CC1N2C=NC=C2C2=CC=CC=C21)O)CC1=CC=CC=C1 Chemical compound O([C@H]1CC[C@@H](CC1)[C@@H](CC1N2C=NC=C2C2=CC=CC=C21)O)CC1=CC=CC=C1 BGZYLMZZDLEDEY-IBXKDZKYSA-N 0.000 description 1
- PPMZDQAMHGXCBF-QIDMFYOTSA-N O([C@H]1CC[C@H](CC1)C(=O)CC1N2C=NC=C2C=2C=CC=C(C1=2)F)CC1=CC=CC=C1 Chemical compound O([C@H]1CC[C@H](CC1)C(=O)CC1N2C=NC=C2C=2C=CC=C(C1=2)F)CC1=CC=CC=C1 PPMZDQAMHGXCBF-QIDMFYOTSA-N 0.000 description 1
- SCWXAHFBXGCWHC-WABOPAKDSA-N OC(CC1c2c(cccc2F)-c2cncn12)[C@@H]1CC[C@@H](CC1)OCc1ccccc1 Chemical compound OC(CC1c2c(cccc2F)-c2cncn12)[C@@H]1CC[C@@H](CC1)OCc1ccccc1 SCWXAHFBXGCWHC-WABOPAKDSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UCXMMPHFNPPJRZ-NQFDUEACSA-N [(2S)-1-[2-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethoxy]-3-methyl-1-oxobutan-2-yl]azanium chloride Chemical compound [Cl-].C1(CCCCC1)C(COC([C@H](C(C)C)[NH3+])=O)C1N2C(C3=CC=CC=C13)=CN=C2 UCXMMPHFNPPJRZ-NQFDUEACSA-N 0.000 description 1
- PPHAPRHPTSQUGI-YOEOTGMDSA-N [(2s)-1-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethoxy]-3-methyl-1-oxobutan-2-yl]azanium;chloride Chemical compound [Cl-].C12=CC=CC=C2C2=CN=CN2C1CC(OC(=O)[C@@H]([NH3+])C(C)C)C1CCCCC1 PPHAPRHPTSQUGI-YOEOTGMDSA-N 0.000 description 1
- YZLOAUVNYJOGOA-JGFIFDEKSA-N [(2s)-1-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethoxy]-3-methyl-1-oxobutan-2-yl]azanium;chloride;hydrochloride Chemical compound Cl.[Cl-].C12=CC=CC=C2C2=CN=CN2C1CC(OC(=O)[C@@H]([NH3+])C(C)C)C1CCCCC1 YZLOAUVNYJOGOA-JGFIFDEKSA-N 0.000 description 1
- UMKSXJURDOMFHY-YMISUZCDSA-N [1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl] (2s)-pyrrolidine-2-carboxylate Chemical compound O=C([C@H]1NCCC1)OC(CC1N2C=NC=C2C2=CC=CC=C21)C1CCCCC1 UMKSXJURDOMFHY-YMISUZCDSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001503 aryl iodides Chemical class 0.000 description 1
- HUZCTWYDQIQZPM-UHFFFAOYSA-N benzyl 2,2,2-trichloroethanimidate Chemical compound ClC(Cl)(Cl)C(=N)OCC1=CC=CC=C1 HUZCTWYDQIQZPM-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- ROBXZHNBBCHEIQ-UHFFFAOYSA-N ethyl 2-aminopropanoate Chemical compound CCOC(=O)C(C)N ROBXZHNBBCHEIQ-UHFFFAOYSA-N 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000022766 lymph node neoplasm Diseases 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- CNTNIDHTVUDBAW-UHFFFAOYSA-N methyl 1-(2,2-dimethylpropanoyl)piperidine-4-carboxylate Chemical compound COC(=O)C1CCN(C(=O)C(C)(C)C)CC1 CNTNIDHTVUDBAW-UHFFFAOYSA-N 0.000 description 1
- AXJFDBZELZYVTN-UHFFFAOYSA-N methyl 1-(thiophene-2-carbonyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C(=O)C1=CC=CS1 AXJFDBZELZYVTN-UHFFFAOYSA-N 0.000 description 1
- OZLXTILQGQWOLV-UHFFFAOYSA-N methyl 3-fluoro-2-(1-tritylimidazol-4-yl)benzoate Chemical compound COC(=O)C1=CC=CC(F)=C1C1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 OZLXTILQGQWOLV-UHFFFAOYSA-N 0.000 description 1
- HYDYVXROZHFTGB-UHFFFAOYSA-N methyl 4-hydroxycyclohexane-1-carboxylate Chemical compound COC(=O)C1CCC(O)CC1 HYDYVXROZHFTGB-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- KJACTJCUOAPGNQ-UHFFFAOYSA-N n-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]acetamide Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(NC(=O)C)C1CCCCC1 KJACTJCUOAPGNQ-UHFFFAOYSA-N 0.000 description 1
- MMUUOCZEFMSKGV-UHFFFAOYSA-N n-[2-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexyl]acetamide Chemical compound CC(=O)NC1CCCCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 MMUUOCZEFMSKGV-UHFFFAOYSA-N 0.000 description 1
- XGXIYSFXMYLWCL-UHFFFAOYSA-N n-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 XGXIYSFXMYLWCL-UHFFFAOYSA-N 0.000 description 1
- MLIIRCUDJAEHTO-UHFFFAOYSA-N n-[4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexyl]-2-phenylacetamide Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1NC(=O)CC1=CC=CC=C1 MLIIRCUDJAEHTO-UHFFFAOYSA-N 0.000 description 1
- HBHJJHJDVFXZGH-UHFFFAOYSA-N n-[4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexyl]benzamide Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1NC(=O)C1=CC=CC=C1 HBHJJHJDVFXZGH-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical class OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- FOEYMRPOKBCNCR-UHFFFAOYSA-N spiro[2.5]octane Chemical compound C1CC11CCCCC1 FOEYMRPOKBCNCR-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475788P | 2011-04-15 | 2011-04-15 | |
| US201161475788P | 2011-04-15 | ||
| PCT/US2012/033245 WO2012142237A1 (en) | 2011-04-15 | 2012-04-12 | Fused imidazole derivatives useful as ido inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2569665T3 true ES2569665T3 (es) | 2016-05-12 |
Family
ID=45976556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12715295.7T Active ES2569665T3 (es) | 2011-04-15 | 2012-04-12 | Derivados de imidazol condensados útiles como inhibidores de IDO |
| ES15197593.5T Active ES2660831T3 (es) | 2011-04-15 | 2012-04-12 | Derivados de imidazol condensados útiles como inhibidores de IDO |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15197593.5T Active ES2660831T3 (es) | 2011-04-15 | 2012-04-12 | Derivados de imidazol condensados útiles como inhibidores de IDO |
Country Status (30)
Families Citing this family (285)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2694640T3 (cg-RX-API-DMAC7.html) | 2011-04-15 | 2018-03-17 | ||
| WO2013009701A2 (en) | 2011-07-08 | 2013-01-17 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| SG10201707545XA (en) * | 2013-03-14 | 2017-10-30 | Newlink Genetics Corp | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
| SG11201507395PA (en) | 2013-03-14 | 2015-10-29 | Curadev Pharma Private Ltd | Inhibitors of the kynurenine pathway |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN103382187B (zh) * | 2013-08-06 | 2015-06-03 | 信实生物医药（上海）有限公司 | 一种3-氯-7(5)-溴苯并异恶唑的合成方法 |
| EA032469B1 (ru) | 2013-12-24 | 2019-05-31 | Бристол-Маерс Сквибб Компани | Новые трициклические соединения в качестве противораковых средств |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| PT3151921T (pt) | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| SG11201700579XA (en) * | 2014-09-05 | 2017-02-27 | Merck Patent Gmbh | Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer |
| GB201417369D0 (en) * | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
| GB201418300D0 (en) * | 2014-10-15 | 2014-11-26 | Redx Pharma Ltd | Compounds |
| HUE054526T2 (hu) | 2014-10-29 | 2021-09-28 | Bicyclerd Ltd | MT1-MMP-ra specifikus biciklusos peptid ligandumok |
| ES2807182T3 (es) | 2014-11-21 | 2021-02-22 | Bristol Myers Squibb Co | Anticuerpos frente a CD73 y sus usos |
| US10525035B2 (en) | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| TW201630907A (zh) | 2014-12-22 | 2016-09-01 | 必治妥美雅史谷比公司 | ＴＧＦβＲ拮抗劑 |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
| CN105884828A (zh) * | 2015-02-16 | 2016-08-24 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| AU2016226468B2 (en) | 2015-03-02 | 2020-10-22 | Bristol-Myers Squibb Company | TGF-beta inhibitors |
| MX2017012729A (es) | 2015-04-03 | 2017-11-15 | Bristol Myers Squibb Co | Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer. |
| WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
| KR20170137165A (ko) * | 2015-04-10 | 2017-12-12 | 베이진 엘티디 | 인돌아민 및/또는 트립토판 2,3-디옥시게나아제로서 신규한 5 또는 8-치환된 이미다조[1,5-a]피리딘 |
| WO2016165613A1 (en) | 2015-04-12 | 2016-10-20 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as ido and tdo inhibitors |
| JP6971850B2 (ja) | 2015-04-13 | 2021-11-24 | ファイヴ プライム セラピューティクス インク | がんの併用療法 |
| AU2016250976B2 (en) * | 2015-04-21 | 2020-02-27 | Jiangsu Hengrui Medicine Co., Ltd. | Imidazo isoindole derivative, preparation method therefor and medical use thereof |
| WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| EP3307740B1 (en) | 2015-05-12 | 2019-12-18 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
| RS63897B1 (sr) | 2015-05-29 | 2023-02-28 | Bristol Myers Squibb Co | Antitela protiv ox40 i njihova primena |
| GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
| CN106256830B (zh) * | 2015-06-18 | 2019-03-08 | 成都海创药业有限公司 | 一种氘代的ido抑制剂及其制备方法和用途 |
| CA2990015A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| CN105037371A (zh) * | 2015-06-30 | 2015-11-11 | 西华大学 | 一种氘代的吲哚胺-2,3-双加氧酶抑制剂 |
| GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| CA2992016C (en) | 2015-07-24 | 2019-10-22 | Newlink Genetics Corporation | Salts and prodrugs of 1-methyl-d-tryptophan |
| US10399987B2 (en) | 2015-07-28 | 2019-09-03 | Bristol-Myer Squibb Company | TGF beta receptor antagonists |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| KR20180042370A (ko) | 2015-08-25 | 2018-04-25 | 브리스톨-마이어스 스큅 컴퍼니 | Tgf 베타 수용체 길항제 |
| CN106478634B (zh) * | 2015-09-01 | 2020-05-22 | 尚华医药科技(江西)有限公司 | 稠合咪唑化合物、其制备方法、药物组合物和用途 |
| US10308647B2 (en) | 2015-10-29 | 2019-06-04 | Scifluor Life Sciences, Inc. | Fused imidazole derivatives as IDO/TDO inhibitors |
| MX2018005517A (es) | 2015-11-02 | 2018-11-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer. |
| CN108026565A (zh) * | 2015-11-09 | 2018-05-11 | 豪夫迈·罗氏有限公司 | 用于鉴定ido1和/或tdo调节剂的筛选测定法 |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| CA3004794A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
| KR102738306B1 (ko) | 2015-12-15 | 2024-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | Cxcr4 수용체 길항제 |
| EP3394068B1 (en) * | 2015-12-24 | 2024-09-11 | Genentech, Inc. | Tdo2 inhibitors |
| CN107056785B (zh) * | 2016-01-02 | 2021-06-22 | 杭州英创医药科技有限公司 | 作为ido和tdo抑制剂的杂环化合物 |
| WO2017134555A1 (en) | 2016-02-02 | 2017-08-10 | Emcure Pharmaceuticals Limited | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer |
| CN112898309A (zh) * | 2016-02-19 | 2021-06-04 | 正大天晴药业集团股份有限公司 | 作为免疫调节剂的三并环化合物 |
| WO2017140272A1 (zh) * | 2016-02-19 | 2017-08-24 | 正大天晴药业集团股份有限公司 | 作为免疫调节剂的三并环化合物 |
| US11752131B2 (en) | 2016-02-19 | 2023-09-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of obesity |
| WO2017149469A1 (en) | 2016-03-03 | 2017-09-08 | Emcure Pharmaceuticals Limited | Heterocyclic compounds useful as ido and/or tdo modulators |
| SG10201913033UA (en) | 2016-03-04 | 2020-03-30 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| CN105732643A (zh) * | 2016-04-18 | 2016-07-06 | 苏州大学 | 一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用 |
| US10865244B2 (en) | 2016-04-18 | 2020-12-15 | Celldex Therapeutics, Inc. | Nucleic acids encoding agonistic antibodies that bind CD40 |
| CN107312005B (zh) * | 2016-04-27 | 2021-12-17 | 上海翰森生物医药科技有限公司 | 具有ido/tdo抑制活性的稠合咪唑衍生物及其制备方法和应用 |
| CN109414420A (zh) | 2016-05-04 | 2019-03-01 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| JP2019522627A (ja) | 2016-05-04 | 2019-08-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| CN109414421A (zh) | 2016-05-04 | 2019-03-01 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| JP2019516681A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| EP3452451A4 (en) | 2016-05-04 | 2019-11-13 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN107383012B (zh) * | 2016-05-16 | 2021-09-28 | 鲁南制药集团股份有限公司 | 含二环的咪唑醇衍生物 |
| CN107556316B (zh) * | 2016-06-30 | 2021-11-12 | 鲁南制药集团股份有限公司 | 含桥环的咪唑衍生物 |
| WO2017198159A1 (zh) * | 2016-05-16 | 2017-11-23 | 鲁南制药集团股份有限公司 | 含桥环的咪唑衍生物 |
| CN105902542A (zh) * | 2016-05-16 | 2016-08-31 | 张阳 | 一种偶联物在制备治疗心血管疾病药物中的应用 |
| CN106957318B (zh) * | 2016-05-19 | 2019-12-10 | 中国科学院上海有机化学研究所 | 稠合多环吲哚啉化合物、其制备方法、药物组合物及应用 |
| US11246877B2 (en) | 2016-05-20 | 2022-02-15 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
| AR108586A1 (es) | 2016-06-10 | 2018-09-05 | Lilly Co Eli | Compuestos de 2,3-dihidro-1h-indol |
| CN107488179B (zh) * | 2016-06-11 | 2024-06-07 | 鲁南制药集团股份有限公司 | 含桥环的咪唑醇衍生物 |
| CN107556315B (zh) * | 2016-06-30 | 2021-08-31 | 鲁南制药集团股份有限公司 | 含四元环的咪唑衍生物 |
| EP4512829A3 (en) | 2016-07-14 | 2025-06-11 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
| CN107663159A (zh) * | 2016-07-29 | 2018-02-06 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| WO2018028491A1 (zh) * | 2016-08-09 | 2018-02-15 | 苏州国匡医药科技有限公司 | 吲哚胺2，3-双加氧酶抑制剂及其在药学中的用途 |
| JP2019528300A (ja) | 2016-08-26 | 2019-10-10 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法 |
| WO2018045966A1 (zh) * | 2016-09-12 | 2018-03-15 | 广州必贝特医药技术有限公司 | 含咪唑稠合三环类化合物及其应用 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| EP3515914A4 (en) | 2016-09-24 | 2020-04-15 | BeiGene, Ltd. | NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES |
| CA3037387A1 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| TW201815793A (zh) * | 2016-10-21 | 2018-05-01 | 江蘇恆瑞醫藥股份有限公司 | 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法 |
| WO2018072743A1 (zh) * | 2016-10-21 | 2018-04-26 | 苏州盛迪亚生物医药有限公司 | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 |
| JP7096817B2 (ja) | 2016-11-04 | 2022-07-06 | オークランド ユニサービシーズ リミティド | 三環式複素環式誘導体及びその使用 |
| CN106474468B (zh) * | 2016-11-23 | 2020-03-27 | 中国医学科学院医学生物学研究所 | 一种复合佐剂、含该复合佐剂的疫苗及疫苗的制备方法 |
| WO2018106579A1 (en) * | 2016-12-06 | 2018-06-14 | Albert Einstein College Of Medicine, Inc. | Drug targeting of human indoleamine 2,3-dioxygenase |
| EP3560928B1 (en) * | 2016-12-20 | 2021-10-20 | Shenzhen Chipscreen Biosciences Co., Ltd. | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity |
| SG10201911243WA (en) | 2016-12-22 | 2020-02-27 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| CN108239091B (zh) * | 2016-12-26 | 2021-08-13 | 中国医学科学院药物研究所 | 1-环己基-2-(5H-咪唑[5,1-a]异吲哚)乙基-1-酮的拆分 |
| WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| CN110191709A (zh) | 2017-01-17 | 2019-08-30 | 德州大学系统董事会 | 可用作吲哚胺2,3-双加氧酶和/或色氨酸双加氧酶抑制剂的化合物 |
| WO2018175954A1 (en) | 2017-03-23 | 2018-09-27 | F. Hoffmann-La Roche Ag | Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors |
| WO2018183608A1 (en) | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| US10570138B2 (en) | 2017-04-21 | 2020-02-25 | Kyn Therapeutics | Indole AHR inhibitors and uses thereof |
| EP3628070B1 (en) | 2017-04-28 | 2021-09-08 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides for use in increasing central memory t cells |
| WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN107176956B (zh) * | 2017-05-31 | 2019-11-12 | 成都海博锐药业有限公司 | 一种ido抑制剂化合物、药用组合物、用途 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP3645537A1 (en) | 2017-06-28 | 2020-05-06 | Genentech, Inc. | Tdo2 and ido1 inhibitors |
| EP3645533B1 (en) | 2017-06-28 | 2025-03-26 | Genentech, Inc. | Tdo2 and ido1 inhibitors |
| IL271601B2 (en) | 2017-06-30 | 2024-05-01 | Bristol Myers Squibb Co | Amorphous and crystalline forms of ido inhibitors |
| KR102709265B1 (ko) | 2017-07-28 | 2024-09-23 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| EP3638367A4 (en) | 2017-08-02 | 2021-07-21 | The University of Chicago | NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE |
| EP3661948B1 (en) | 2017-08-04 | 2022-06-01 | BicycleTx Limited | Bicyclic peptide ligands specific for cd137 |
| CN109983019B (zh) * | 2017-08-08 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | 一种咪唑并异吲哚类衍生物的制备方法 |
| CN109384791B (zh) * | 2017-08-09 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法 |
| JP7269917B2 (ja) | 2017-08-17 | 2023-05-09 | イケナ オンコロジー， インコーポレイテッド | Ａｈｒ阻害剤およびその使用 |
| JP7110325B2 (ja) | 2017-08-17 | 2022-08-01 | イドーシア ファーマシューティカルズ リミテッド | インドールアミン ２，３－ジオキシゲナーゼ及び／又はトリプトファン ２，３－ジオキシゲナーゼの阻害剤 |
| EP3670518A4 (en) | 2017-08-18 | 2021-01-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TRICYCLIC COMPOUND CRYSTALS |
| WO2019040102A1 (en) * | 2017-08-22 | 2019-02-28 | Gilead Sciences, Inc. | THERAPEUTIC HETEROCYCLIC COMPOUNDS |
| EP3676278B1 (en) | 2017-08-31 | 2023-04-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| JP7316263B2 (ja) | 2017-08-31 | 2023-07-27 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| US10953032B2 (en) | 2017-08-31 | 2021-03-23 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| CN107501272B (zh) * | 2017-09-05 | 2020-03-31 | 中国药科大学 | 咪唑并异吲哚类ido1抑制剂、其制备方法及应用 |
| EP3681498B1 (en) | 2017-09-14 | 2022-10-05 | Lankenau Institute for Medical Research | Methods and compositions for the treatment of cancer |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス， インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
| US11203592B2 (en) | 2017-10-09 | 2021-12-21 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| CN111344297B (zh) | 2017-10-10 | 2023-10-20 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
| US11427610B2 (en) | 2017-10-16 | 2022-08-30 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019078246A1 (ja) | 2017-10-19 | 2019-04-25 | 一般社団法人ファルマバレープロジェクト支援機構 | Ｉｄｏ／ｔｄｏ阻害剤 |
| KR20200074214A (ko) | 2017-11-01 | 2020-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체 |
| EP3707138B1 (en) | 2017-11-06 | 2022-07-13 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| WO2019101188A1 (en) | 2017-11-25 | 2019-05-31 | Beigene, Ltd. | Novel benzoimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenases |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| KR102813744B1 (ko) | 2017-12-27 | 2025-05-28 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd40 항체 및 그의 용도 |
| US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| ES2907282T3 (es) | 2018-01-15 | 2022-04-22 | Idorsia Pharmaceuticals Ltd | Inhibidores de la indoleamina 2,3-dioxigenasa y/o de la triptófano dioxigenasa |
| WO2019141095A1 (zh) * | 2018-01-19 | 2019-07-25 | 四川科伦博泰生物医药股份有限公司 | 脒类和胍类衍生物、其制备方法及其在医药上的应用 |
| SG11202006701TA (en) | 2018-01-29 | 2020-08-28 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
| MX2020007797A (es) | 2018-01-29 | 2020-09-18 | Merck Patent Gmbh | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. |
| US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| SG11202007678QA (en) | 2018-02-23 | 2020-09-29 | Bicycletx Ltd | Multimeric bicyclic peptide ligands |
| JP7250808B2 (ja) | 2018-03-08 | 2023-04-03 | ブリストル－マイヤーズ スクイブ カンパニー | 抗がん剤としての環状ジヌクレオチド |
| US11149011B2 (en) | 2018-03-20 | 2021-10-19 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
| KR102874694B1 (ko) | 2018-03-21 | 2025-10-23 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
| KR20200142542A (ko) | 2018-04-12 | 2020-12-22 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법 |
| CN112292128A (zh) | 2018-04-16 | 2021-01-29 | 阿瑞斯医疗有限公司 | Ep4抑制剂和其用途 |
| US12037323B2 (en) | 2018-05-03 | 2024-07-16 | Bristol-Myers Squibb Company | Uracil derivatives as Mer-AXL inhibitors |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| CN112654621B (zh) | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| EA202190137A1 (ru) | 2018-06-27 | 2021-05-17 | Бристол-Маерс Сквибб Компани | Нафтиридиноновые соединения для применения в качестве активаторов t-клеток |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| EP3820904A2 (en) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
| CN121203021A (zh) | 2018-07-11 | 2025-12-26 | 戊瑞治疗有限公司 | 在酸性pH下结合至VISTA的抗体 |
| US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| WO2020023356A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12059420B2 (en) | 2018-07-23 | 2024-08-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| EP3858813A4 (en) * | 2018-09-27 | 2022-06-22 | Shenzhen Chipscreen Biosciences Co., Ltd. | QUINOLONE DERIVATIVE WITH INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY |
| CN113164780A (zh) | 2018-10-10 | 2021-07-23 | 泰洛斯治疗公司 | 抗lap抗体变体及其用途 |
| PE20211284A1 (es) | 2018-11-16 | 2021-07-19 | Bristol Myers Squibb Co | Anticuerpos anti-nkg2a y usos de los mismos |
| KR20250167680A (ko) | 2018-11-30 | 2025-12-01 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| CN113453679B (zh) | 2018-12-20 | 2025-07-08 | C4医药公司 | 靶向蛋白降解 |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| CN113795264A (zh) | 2019-03-19 | 2021-12-14 | 瓦尔希伯伦私人肿瘤研究基金会 | 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法 |
| EP3946462A1 (en) | 2019-04-02 | 2022-02-09 | BicycleTX Limited | Bicycle toxin conjugates and uses thereof |
| CA3135802A1 (en) | 2019-04-05 | 2020-10-08 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
| WO2020231766A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| CA3146406A1 (en) | 2019-07-11 | 2021-01-14 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
| US20220306630A1 (en) | 2019-08-06 | 2022-09-29 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| JP2022547719A (ja) | 2019-09-13 | 2022-11-15 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニストおよびその使用 |
| EP4031575A1 (en) | 2019-09-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| MX2022005839A (es) | 2019-11-19 | 2022-06-09 | Bristol Myers Squibb Co | Compuestos utiles como inhibidores de la proteina helios. |
| CN115151306A (zh) | 2019-11-26 | 2022-10-04 | 百时美施贵宝公司 | (r)-n-(4-氯苯基)-2-((1s，4s)-4-(6-氟喹啉-4-基)环己基)丙酰胺的盐/共晶 |
| PL4065582T3 (pl) | 2019-11-26 | 2025-08-18 | Ikena Oncology, Inc. | Polimorficzne pochodne karbazolu i ich zastosowania |
| CN111333653A (zh) * | 2019-12-16 | 2020-06-26 | 山东大学 | 一种icd诱导剂-ido抑制剂缀合物及制备方法与应用 |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| IL294273A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted heteroaryl compounds are useful as t-cell activators |
| EP4081513B1 (en) | 2019-12-23 | 2024-11-20 | Bristol-Myers Squibb Company | Substituted quinolinonyl piperazine compounds useful as t cell activators |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| KR20220120624A (ko) | 2019-12-23 | 2022-08-30 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 피페라진 유도체 |
| AU2020415377A1 (en) | 2019-12-23 | 2022-08-18 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as T cell activators |
| AU2020412780A1 (en) | 2019-12-23 | 2022-07-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| EP4087874A1 (en) | 2020-01-06 | 2022-11-16 | HiFiBiO (HK) Limited | Anti-tnfr2 antibody and uses thereof |
| US20230054718A1 (en) | 2020-01-07 | 2023-02-23 | Hifibio (Hk) Limited | Anti-galectin-9 antibody and uses thereof |
| CN115279771B (zh) | 2020-01-15 | 2025-03-21 | 缆图药品公司 | Map4k1抑制剂 |
| TW202146393A (zh) | 2020-03-03 | 2021-12-16 | 美商皮克醫療公司 | Eif4e抑制劑及其用途 |
| WO2021183428A1 (en) | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| KR20230005160A (ko) | 2020-03-19 | 2023-01-09 | 카이메라 쎄라퓨틱스 인코포레이티드 | Mdm2 분해제 및 이의 용도 |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| WO2021247897A1 (en) | 2020-06-03 | 2021-12-09 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
| CN111803635B (zh) * | 2020-06-17 | 2023-03-14 | 中国医学科学院基础医学研究所 | 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用 |
| WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| MX2023001217A (es) | 2020-07-30 | 2023-03-03 | Kymera Therapeutics Inc | Metodos de tratamiento de linfomas mutantes. |
| MX2023001707A (es) | 2020-08-10 | 2023-05-04 | Shanghai Xunbaihui Biotechnology Co Ltd | Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas. |
| MX2023001588A (es) | 2020-08-17 | 2023-05-03 | Bicycletx Ltd | Conjugados biciclo específicos para nectina-4 y usos de estos. |
| EP4228764A1 (en) | 2020-10-14 | 2023-08-23 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| KR20230131189A (ko) | 2020-12-02 | 2023-09-12 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| JP2024501207A (ja) | 2020-12-16 | 2024-01-11 | ゴッサマー バイオ サービシズ、インコーポレイテッド | Ｔ細胞活性化剤として有用な化合物 |
| JP2024503300A (ja) | 2020-12-30 | 2024-01-25 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| US20250186539A2 (en) | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
| CN117098757A (zh) | 2021-02-02 | 2023-11-21 | 里米诺生物科学有限公司 | Gpr84拮抗剂和其用途 |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| WO2022169921A1 (en) | 2021-02-04 | 2022-08-11 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
| WO2022174253A1 (en) | 2021-02-12 | 2022-08-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| CA3210553A1 (en) | 2021-02-12 | 2022-08-18 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
| CN116867494A (zh) | 2021-02-15 | 2023-10-10 | 凯麦拉医疗公司 | Irak4降解剂和其用途 |
| TW202245788A (zh) | 2021-02-15 | 2022-12-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其用途 |
| MX2023010371A (es) | 2021-03-05 | 2024-02-12 | Univ Basel | Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb. |
| WO2022187856A1 (en) | 2021-03-05 | 2022-09-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| WO2022192145A1 (en) | 2021-03-08 | 2022-09-15 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
| US12071442B2 (en) | 2021-03-29 | 2024-08-27 | Nimbus Saturn, Inc. | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists |
| WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| BR112023020410A2 (pt) | 2021-04-05 | 2023-11-28 | Bristol Myers Squibb Co | Compostos de oxoisoindolina substituída por piridinila para tratamento de câncer |
| WO2022216644A1 (en) | 2021-04-06 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
| CA3214952A1 (en) | 2021-04-09 | 2022-10-13 | Silvana Marcel LEIT DE MORADEI | Cbl-b modulators and uses thereof |
| WO2022221866A1 (en) | 2021-04-16 | 2022-10-20 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2022236058A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| AR126442A1 (es) | 2021-07-14 | 2023-10-11 | Blueprint Medicines Corp | Inhibidores de map4k1 |
| AR126453A1 (es) | 2021-07-15 | 2023-10-11 | Blueprint Medicines Corp | Inhibidores de map4k1 |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| CN118103368A (zh) | 2021-08-25 | 2024-05-28 | 皮克医疗公司 | Eif4e抑制剂及其用途 |
| AU2022378630A1 (en) | 2021-10-29 | 2024-05-09 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| WO2023122772A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122778A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Pyridazinone derivatives useful as t cell activators |
| WO2023122777A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| JP2025504059A (ja) | 2022-01-31 | 2025-02-06 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋデグレーダー及びその使用 |
| WO2023150186A1 (en) | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| CN119768393A (zh) | 2022-05-25 | 2025-04-04 | 医肯纳肿瘤学公司 | Mek抑制剂和其用途 |
| KR20250057800A (ko) | 2022-08-02 | 2025-04-29 | 리미널 바이오사이언시스 리미티드 | 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도 |
| WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| IL318576A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | Pyridoxine-substituted GPR84 antagonists and their uses |
| EP4568950A1 (en) | 2022-08-08 | 2025-06-18 | Bristol-Myers Squibb Company | Substituted tetrazolyl compounds useful as t cell activators |
| WO2024036101A1 (en) | 2022-08-09 | 2024-02-15 | Bristol-Myers Squibb Company | Tertiary amine substituted bicyclic compounds useful as t cell activators |
| CR20250043A (es) | 2022-08-11 | 2025-03-25 | Hoffmann La Roche | Derivados bicíclicos de tetrahidrotiazepina |
| WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
| CN119768401A (zh) | 2022-08-11 | 2025-04-04 | 豪夫迈·罗氏有限公司 | 双环四氢硫氮杂䓬衍生物 |
| JP2025526727A (ja) | 2022-08-11 | 2025-08-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二環式テトラヒドロチアゼピン誘導体 |
| WO2024112894A1 (en) | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| CN116143726B (zh) * | 2022-12-02 | 2024-09-06 | 广州市联瑞制药有限公司 | 一种环磷腺苷杂质的制备方法 |
| WO2024137865A1 (en) | 2022-12-22 | 2024-06-27 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| KR20250019700A (ko) | 2023-05-08 | 2025-02-10 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 페닐 옥사졸론 화합물 |
| TW202509014A (zh) | 2023-05-10 | 2025-03-01 | 美商纜圖藥品公司 | ＧＳＫ３α抑制劑及其使用方法 |
| WO2024249540A1 (en) | 2023-05-31 | 2024-12-05 | Bristol-Myers Squibb Company | Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins |
| WO2024254227A1 (en) | 2023-06-07 | 2024-12-12 | Bristol-Myers Squibb Company | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound |
| WO2024263853A1 (en) | 2023-06-23 | 2024-12-26 | Bristol-Myers Squibb Company | Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent |
| EP4615455A2 (en) | 2023-06-23 | 2025-09-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2025030002A2 (en) | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| EP4568957A1 (en) | 2023-09-02 | 2025-06-18 | Bristol-Myers Squibb Company | Substituted phenyl oxooxazolyl piperidine dione compounds |
| WO2025064197A1 (en) | 2023-09-02 | 2025-03-27 | Bristol-Myers Squibb Company | Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds |
| AR133800A1 (es) | 2023-09-13 | 2025-11-05 | Bristol Myers Squibb Co | Compuestos de oxoisoindolinil piperidina-2,6-diona sustituida |
| WO2025096489A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| US20250145590A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096490A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096488A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096505A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096494A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096487A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025226767A1 (en) | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| CN119707950A (zh) * | 2024-12-24 | 2025-03-28 | 无锡市南京大学锡山应用生物技术研究所 | 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3476195D1 (en) | 1983-05-18 | 1989-02-23 | Ciba Geigy Ag | Cyclohexanedione-carboxylic-acid derivatives having a herbicidal and plant growth regulating activity |
| US5807892A (en) | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| US6451840B1 (en) | 1997-12-05 | 2002-09-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by tryptophan |
| US20030194803A1 (en) | 2002-04-12 | 2003-10-16 | Mellor Andrew L. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| WO2004093871A1 (en) | 2003-03-27 | 2004-11-04 | Lankenau Institute For Medical Research | Novel methods for the treatment of cancer |
| US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| WO2005074603A2 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| CN101212967A (zh) | 2005-05-10 | 2008-07-02 | 因塞特公司 | 吲哚胺2,3-双加氧酶调节剂及其用法 |
| US7705022B2 (en) | 2005-10-27 | 2010-04-27 | Lankenau Institute For Medical Research | IDO inhibitors and methods of use thereof |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| EP2137168B1 (en) | 2007-03-16 | 2016-09-14 | Lankenau Institute for Medical Research | Novel ido inhibitors and methods of use thereof |
| DE102007020493A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Amid-Derivate |
| EP2227233B1 (en) * | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
| EP2231656A1 (en) | 2007-12-19 | 2010-09-29 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| CA2722159C (en) * | 2008-04-24 | 2016-04-05 | Newlink Genetics Corporation | Substituted phenylimidazole compounds and their use as ido inhibitors |
| CN104042611B (zh) | 2008-07-08 | 2019-05-14 | 因塞特控股公司 | 作为吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑 |
| ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
| NO2694640T3 (cg-RX-API-DMAC7.html) | 2011-04-15 | 2018-03-17 | ||
| EP2922847A1 (en) | 2012-11-20 | 2015-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
| SG11201507395PA (en) | 2013-03-14 | 2015-10-29 | Curadev Pharma Private Ltd | Inhibitors of the kynurenine pathway |
| SG10201707545XA (en) | 2013-03-14 | 2017-10-30 | Newlink Genetics Corp | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
| WO2014141110A2 (en) | 2013-03-14 | 2014-09-18 | Curadev Pharma Pvt. Ltd. | Aminonitriles as kynurenine pathway inhibitors |
| AU2014235750B2 (en) | 2013-03-15 | 2018-05-17 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (IDO) |
| CA2907178A1 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Ido inhibitors |
| MX2015017486A (es) | 2013-07-01 | 2016-03-21 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (dio). |
| CN105517999B (zh) | 2013-07-11 | 2019-06-28 | 百时美施贵宝公司 | Ido抑制剂 |
-
2012
- 2012-04-05 NO NO12767723A patent/NO2694640T3/no unknown
- 2012-04-12 JP JP2014505274A patent/JP2014511876A/ja not_active Withdrawn
- 2012-04-12 PT PT151975935T patent/PT3018132T/pt unknown
- 2012-04-12 WO PCT/US2012/033245 patent/WO2012142237A1/en not_active Ceased
- 2012-04-12 RU RU2017107026A patent/RU2017107026A/ru unknown
- 2012-04-12 SI SI201230515A patent/SI2697227T1/sl unknown
- 2012-04-12 ES ES12715295.7T patent/ES2569665T3/es active Active
- 2012-04-12 RS RS20160285A patent/RS54723B1/sr unknown
- 2012-04-12 CA CA2833296A patent/CA2833296C/en active Active
- 2012-04-12 EP EP12715295.7A patent/EP2697227B1/en active Active
- 2012-04-12 ME MEP-2016-82A patent/ME02417B/me unknown
- 2012-04-12 PL PL12715295.7T patent/PL2697227T3/pl unknown
- 2012-04-12 KR KR1020137030438A patent/KR102164443B1/ko active Active
- 2012-04-12 EP EP15197593.5A patent/EP3018132B1/en active Active
- 2012-04-12 DK DK12715295.7T patent/DK2697227T3/en active
- 2012-04-12 NZ NZ708090A patent/NZ708090A/en unknown
- 2012-04-12 HR HRP20160369TT patent/HRP20160369T1/hr unknown
- 2012-04-12 PE PE2013002332A patent/PE20141124A1/es active IP Right Grant
- 2012-04-12 SI SI201231193T patent/SI3018132T1/en unknown
- 2012-04-12 EP EP17205515.4A patent/EP3348558A1/en not_active Withdrawn
- 2012-04-12 NZ NZ723271A patent/NZ723271A/en unknown
- 2012-04-12 LT LTEP15197593.5T patent/LT3018132T/lt unknown
- 2012-04-12 HU HUE15197593A patent/HUE038586T2/hu unknown
- 2012-04-12 MX MX2013012021A patent/MX340442B/es active IP Right Grant
- 2012-04-12 PE PE2017002751A patent/PE20181023A1/es not_active Application Discontinuation
- 2012-04-12 ES ES15197593.5T patent/ES2660831T3/es active Active
- 2012-04-12 PL PL15197593T patent/PL3018132T3/pl unknown
- 2012-04-12 CN CN201510262906.5A patent/CN105111210B/zh active Active
- 2012-04-12 BR BR112013026494A patent/BR112013026494A2/pt not_active Application Discontinuation
- 2012-04-12 DK DK15197593.5T patent/DK3018132T3/en active
- 2012-04-12 HU HUE12715295A patent/HUE027316T2/en unknown
- 2012-04-12 RS RS20180223A patent/RS56992B1/sr unknown
- 2012-04-12 CN CN201280018684.7A patent/CN103547579B/zh active Active
- 2012-04-12 RU RU2013150811A patent/RU2613579C2/ru active
- 2012-04-12 AU AU2012242871A patent/AU2012242871C1/en active Active
-
2013
- 2013-10-14 IL IL228862A patent/IL228862A/en active IP Right Grant
- 2013-10-14 US US14/053,440 patent/US9260434B2/en active Active
- 2013-10-15 CL CL2013002990A patent/CL2013002990A1/es unknown
- 2013-11-14 CO CO13268287A patent/CO6862146A2/es active IP Right Grant
-
2014
- 2014-12-10 AU AU2014274564A patent/AU2014274564B2/en active Active
- 2014-12-22 JP JP2014258630A patent/JP5837673B2/ja active Active
-
2015
- 2015-07-08 US US14/794,193 patent/US9388191B2/en active Active
- 2015-09-24 IL IL241846A patent/IL241846A/en active IP Right Grant
- 2015-11-05 JP JP2015217361A patent/JP6145491B2/ja active Active
-
2016
- 2016-04-27 CY CY20161100355T patent/CY1117440T1/el unknown
- 2016-05-04 SM SM201600130T patent/SMT201600130B/it unknown
- 2016-06-13 US US15/181,062 patent/US9850248B2/en active Active
- 2016-06-28 IL IL246515A patent/IL246515B/en active IP Right Grant
- 2016-12-20 AU AU2016277574A patent/AU2016277574B2/en active Active
-
2017
- 2017-05-15 JP JP2017096307A patent/JP2017149769A/ja not_active Withdrawn
- 2017-11-01 US US15/800,190 patent/US10233190B2/en active Active
-
2018
- 2018-02-26 HR HRP20180335TT patent/HRP20180335T1/hr unknown
- 2018-04-18 AU AU2018202706A patent/AU2018202706A1/en not_active Abandoned
- 2018-12-03 HK HK18115442.2A patent/HK1256355A1/en unknown
-
2019
- 2019-02-07 US US16/269,681 patent/US20190225618A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2569665T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| ES2963417T3 (es) | Derivados de imidazol condensados como moduladores de IL-17 | |
| AU2018391675B2 (en) | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | |
| JP5612661B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5615352B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| KR102098122B1 (ko) | 피리미도[4,5-b]인돌 유도체 및 조혈 줄기 세포의 증식에서의 이의 용도 | |
| ES2281565T3 (es) | Inhibidores de la integrasa de vih de tipo dihidroxipirimidina carboxamida. | |
| TWI792158B (zh) | 嘧啶酪氨酸激酶抑制劑 | |
| AU2015327411B2 (en) | Boronic acid derivatives | |
| ES2550312T3 (es) | Antagonistas ciclohexil-azetidinilo de CCR2 | |
| AU2015327412B2 (en) | Boronic acid derivatives | |
| JP2021531257A (ja) | Ｉｌ−１７モジュレーターとしてのスピロ環状インダン類似体 | |
| EA020777B1 (ru) | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus | |
| ES2576555T3 (es) | Derivados de piperidina como antagonistas de NK1 | |
| JP2010527373A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| TR201907763T4 (tr) | Ror-gama-t modülatörleri olarak triflorometil alkoller. | |
| IL301055A (en) | Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof | |
| TW202115078A (zh) | 咪唑並[2,1-f][1,2,4]三嗪-4-胺衍生物作為tlr8促效劑 | |
| JP6333826B2 (ja) | アザインドリン | |
| PT96138A (pt) | Processo para a preparacao de compostos ciclo-heptimidazolona,uteis como antagonistas de angiotensina ii, para o controlo da hipertensao | |
| CN115210237B (zh) | 一种二氢嘧啶类化合物、其制备方法及其应用 | |
| TW201713622A (zh) | 含氮雜環化合物 | |
| JP2023527792A (ja) | Ｔｌｒ２調節剤化合物、医薬組成物、及びそれらの使用 | |
| JP2025521353A (ja) | Ｍａｇｌ用蛍光プローブ | |
| KR20150068464A (ko) | 매크로사이클릭 케토아미드 면역프로테아좀 억제제 |